{
    "cancer_info": {
        "cancer_name": "Acute Myeloid Leukemia (AML)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Complete blood count (CBC)",
            "Coagulation panel (PT/PTT/fibrinogen)",
            "LDH and uric acid testing",
            "Bone marrow aspirate/biopsy with morphology",
            "Cytogenetic analysis (karyotyping/FISH)",
            "Flow cytometry immunophenotyping",
            "Molecular studies: NPM1, FLT3-ITD/TKD, CEBPA, IDH1/IDH2, TP53, RUNX1, ASXL1",
            "Next-generation sequencing (NGS) panels",
            "Echocardiogram/MUGA (pre-anthracycline)",
            "Lumbar puncture for CNS evaluation (symptomatic/high-risk)",
            "HLA typing",
            "FDG-PET/CT for extramedullary disease",
            "Quantitative RT-PCR for PML-RARA (APL)",
            "Skin biopsy (BPDCN)",
            "Lymph node biopsy (BPDCN)",
            "CSF analysis with flow cytometry (BPDCN CNS evaluation)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "ELN 2022 Risk Groups",
            "risk_group": "Favorable",
            "treatment_plans": [
                {
                    "treatment_line": "First-line induction",
                    "patient_subgroup": "Fit patients",
                    "plan_name": "7+3 + Gemtuzumab",
                    "plan_details": "Cytarabine 100-200 mg/m² continuous infusion days 1-7 + Daunorubicin 60-90 mg/m² days 1-3 or Idarubicin 12 mg/m² days 1-3 + Gemtuzumab ozogamicin 3 mg/m² days 1/4/7 (CD33+)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Post-remission",
                    "plan_name": "HiDAC",
                    "plan_details": "High-dose cytarabine 1.5-3 g/m² every 12 hours for 4-6 cycles ± Gemtuzumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "ELN 2022 Risk Groups",
            "risk_group": "Intermediate",
            "treatment_plans": [
                {
                    "treatment_line": "First-line induction",
                    "patient_subgroup": "FLT3-mutated",
                    "plan_name": "7+3 + Midostaurin",
                    "plan_details": "Cytarabine + Daunorubicin/Idarubicin + Midostaurin 50mg BID days 8-21",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Post-remission",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "Preferred if donor available",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "ELN 2022 Risk Groups",
            "risk_group": "Adverse",
            "treatment_plans": [
                {
                    "treatment_line": "First-line induction",
                    "patient_subgroup": "Age ≥60 or secondary AML",
                    "plan_name": "CPX-351",
                    "plan_details": "Liposomal cytarabine-daunorubicin 100u/m² days 1, 3, 5",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line induction",
                    "patient_subgroup": "Unfit patients",
                    "plan_name": "Venetoclax + HMA",
                    "plan_details": "Venetoclax (ramp-up to 400mg daily) + Azacitidine 75mg/m² days 1-7 or Decitabine 20mg/m² days 1-5",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Post-remission",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "Strongly recommended if eligible",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "APL Risk Groups",
            "risk_group": "Low Risk (WBC ≤10 × 10⁹/L)",
            "treatment_plans": [
                {
                    "treatment_line": "Induction",
                    "patient_subgroup": "Newly diagnosed",
                    "plan_name": "ATRA + ATO",
                    "plan_details": "All-trans retinoic acid + Arsenic trioxide",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Post-induction",
                    "plan_details": "ATRA + ATO for 4 cycles",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "APL Risk Groups",
            "risk_group": "High Risk (WBC >10 × 10⁹/L)",
            "treatment_plans": [
                {
                    "treatment_line": "Induction",
                    "patient_subgroup": "Newly diagnosed",
                    "plan_name": "ATRA + ATO + Gemtuzumab",
                    "plan_details": "All-trans retinoic acid + Arsenic trioxide + Gemtuzumab ozogamicin 9mg/m² day 1",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Post-induction",
                    "plan_details": "ATRA + ATO ± Gemtuzumab for 4-7 cycles + CNS prophylaxis",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "BPDCN",
            "risk_group": "Newly diagnosed",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "Tagraxofusp",
                    "plan_details": "12 µg/kg IV days 1-5 every 21 days",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Eligible patients",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "In first complete remission",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "CNS Prophylaxis",
                    "patient_subgroup": "All patients",
                    "plan_name": "IT Chemotherapy",
                    "plan_details": "Intrathecal methotrexate/cytarabine twice weekly until CSF clearance",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "FLT3-mutated",
                    "plan_name": "Gilteritinib",
                    "plan_details": "120 mg daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "IDH1-mutated",
                    "plan_name": "Ivosidenib",
                    "plan_details": "500 mg daily ± Azacitidine",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "General AML",
                    "plan_name": "CLAG-M/Venetoclax",
                    "plan_details": "Cladribine + Cytarabine + G-CSF + Mitoxantrone/Venetoclax",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Eligible patients",
                    "plan_name": "Allogeneic HCT",
                    "plan_details": "At second complete remission",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "FLT3-ITD: Predicts response to FLT3 inhibitors (midostaurin/gilteritinib); adverse prognosis if high allelic ratio. NPM1 mutation: Favorable prognosis if FLT3-ITD negative; MRD monitoring marker. TP53 mutation: Very adverse prognosis; predicts resistance to chemotherapy, better response to HMA+Venetoclax. IDH1/2 mutations: Predict response to IDH inhibitors (ivosidenib/enasidenib). CBF-AML: Favorable prognosis; predicts benefit from high-dose cytarabine. CD33 expression: Predicts response to gemtuzumab ozogamicin. PML-RARA fusion: APL-defining; guides ATRA+ATO therapy and MRD monitoring. KMT2A rearrangements: Adverse prognosis; potential response to menin inhibitors."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：急性髓性白血病.txt"
}